Such immunological relevance highlights the multifaceted roles of LPL in tumor immunity regulation and underscores its potential value in immunotherapy, particularly in its interactions with key immune checkpoint molecules like PD-1 and CTLA4, which could significantly influence treatment response rates. The gene discussed is PDCD1; the disease is neoplasm.